345965-99-3

Basic information

• Product Name: 4-bromo-N-cyclopropyl-2-methylbenzamide
• Synonyms: 4-bromo-N-cyclopropyl-2-methylbenzamide
• CAS NO: 345965-99-3
• Molecular Weight: 254.126
• Mol File: 345965-99-3.mol
• Article Data: 24

Chemical Properties

• CAS DataBase Reference: 4-bromo-N-cyclopropyl-2-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-N-cyclopropyl-2-methylbenzamide(345965-99-3)
• EPA Substance Registry System: 4-bromo-N-cyclopropyl-2-methylbenzamide(345965-99-3)

Safety Data

• Hazardous Substances Data: 345965-99-3(Hazardous Substances Data)

Upstream product

• 21900-45-8 4-bromo-2-methylbenzoyl chloride 
• 765-30-0 Cyclopropylamine 
• 68837-59-2 4-bromo-2-methylbenzoic acid 

Downstream Products

• 1610680-36-8 N-cyclopropyl-2-methyl-4-(2-(methylsulfonyl)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamide 
• 1610680-23-3 N-cyclopropyl-2-methyl-4-(2-(methylthio)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamide 
• 1610680-22-2 N-cyclopropyl-4-(4-((4-methoxybenzyl)(2-morpholinoethyl)amino)-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-8-yl)-2-methylbenzamide 
• 1610679-73-6 N-cyclopropyl-4-(4-((4-methoxybenzyl)((tetrahydro-2H-pyran-4-yl)methyl)amino)-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-8-yl)-2-methylbenzamide 
• 1610676-66-8 C₂₈H₂₉F₂N₇O₃*C₂HF₃O₂ 
• 1610676-59-9 N-cyclopropyl-4-(2-(2-fluorophenoxy)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)-2-methylbenzamide 
• 1610676-60-2 N-cyclopropyl-4-(2-(3-fluorophenoxy)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)-2-methylbenzamide 
• 1610676-51-1 N-cyclopropyl-4-(2-(2,3-difluorophenoxy)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)-2-methylbenzamide 
• 1610676-58-8 4-(2-(3-acetamidophenoxy)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)-N-cyclopropyl-2-methylbenzamide 
• 1610676-47-5 N-cyclopropyl-2-methyl-4-(2-(phenylamino)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamide 
• 1610676-27-1 N-cyclopropyl-2-methyl-4-(2-phenoxy-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamide 
• 1610676-50-0 4-(2-(cyclopentyloxy)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)-N-cyclopropyl-2-methylbenzamide 
• 1610676-23-7 4-(2-(cyclopentylamino)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)-N-cyclopropyl-2-methylbenzamide 

Relevant articles and documents

Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent

This work describes a scaffold hopping exercise that begins with known imidazo[1,2-a]pyrazines, briefly explores pyrazolo[1,5-a][1,3,5]triazines, and ultimately yields pyrazolo[1,5-a]pyrimidines as a novel class of potent TTK inhibitors. An X-ray structure of a representative compound is consistent with 11/2 type inhibition and provides structural insight to aid subsequent optimization of in vitro activity and physicochemical and pharmacokinetic properties. Incorporation of polar moieties in the hydrophobic and solvent accessible regions modulates physicochemical properties while maintaining potency. Compounds with enhanced oral exposure were identified for xenograft studies. The work culminates in the identification of a potent (TTK Ki = 0.1 nM), highly selective, orally bioavailable anticancer agent (CFI-402257) for IND enabling studies.

PYRAZOLOPYRIMIDINE COMPOUNDS

The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

COMBINATIONS FOR THE TREATMENT OF CANCER

The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti- apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.